All filters
Abstracts
HIV-1 Integrase Resistance Associated Mutations and the Use of Dolutegravir in Sub- Saharan Africa: A Systematic Review and Meta-Analysis
E. Semengue
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HIV transmission clusters in Europe: A perspective view of Late presenters and Non-Late presenters
Mafalda N.S. Miranda
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Characterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 waves
R. Scutari
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing
M. Bellocchi
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
SARS-CoV-2 mutations and variants may muddle the sensitivity of COVID-19 diagnostic assays
M. Alkhatib
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies
L. Fiaschi
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Levels and durability of humoral and T-specific responses after the booster dose of mRNA BNT162b2 vaccine in residents of a Long Term Care Facility
A. Bergna
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Transmitted drug resistance to integrase based first-line treatment in Europe, 2018-2021
F. Garcia
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HIV-1 Transmitted drug resistance and transmission clusters in newly diagnosed patients in Portugal between 2014 and 2019
M. Pingarilho
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Reaching the 95-95-95 targets will not eliminate HIV transmission in 2030 among individuals born in sub-Saharan Africa residing in the Netherlands
S. Mukherjee
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HIV reservoir quantification by combining total HIV-1 DNA assay and intact proviral DNA assay (IPDA) in one triplex digital PCR reaction
M. Delporte
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Temporal trend of drug- resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals
D. Armenia
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Comparison of Markers of Inflammation and Associated Baseline Variables in Virologically Suppressed Participants in the TANGO Study at Week 144
R. Wang
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Predictors of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings
D. Armenia
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Analysis of mutational history of multi-drug resistant genotypes with a mutagenetic tree model
M. Pirkl
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Changes in the HIV-1 3'- polypurine tract in patients failing dolutegravir in Brazil
J. Kampen
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Using social media to improve follow-up and routine checks on newly diagnosed young people living with HIV and their adherence to Antiretroviral Therapy
K. Owoso
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Resistance analysis of pre- treatment NS3 and NS5A variants in HCV genotype 1a, 1b and 3a infected patients in Croatia
P. Simicic
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Evaluation of the virological efficacy of switching to dolutegravir-based tritherapy in patients followed under real-life conditions in Abidjan, Côte d'Ivoire
J. Dechi
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Major protease resistance in West African HIV-1 subtypes is associated with novel protease mutations and accelerated gag evolution during second-line ART
K. Bouzidi
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Interpretation of the T66I and G118R mutations in integrase in HIV-2
J. Kampen
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Virological characterization of treatment failures and retreatment outcomes in patients infected with “unusual” HCV genotype 1 subtypes
E. Quang
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
The acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancer
L. Piermatteo
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection
S. D'Anna
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022